Singapore AI Biotech Startup Raises $4 Million to Make Medicine Production Smarter and Cheaper

ChemT Biotechnology a Singapore company has secured four million dollars in seed funding to advance its artificial intelligence tools for biomanufacturing.

The round was led by Wavemaker Ventures with participation from SEEDS and other backers.

AI Transforms Cell Behavior Prediction in Factories

The company develops CelMo an AI platform that acts like a virtual cell to simulate responses during production processes.

This technology uses vast amounts of biological data to model growth metabolism and stress in cells such as CHO and T cells.

Investors see potential for higher yields lower costs and faster output in drug manufacturing.

Singapore Hub Status Boosts Global Biotech Innovation

The funding supports work toward good manufacturing practice standards and expansion to more cell types including stem cells.

Chief executive Jie Sun noted quick progress with commercial ties to over forty firms worldwide in just eighteen months.

Biomanufacturing often faces unpredictable cell behavior that AI can now address more precisely than before.

Such advances may lead to more reliable supplies of vaccines and therapies for everyday health needs.

Industry observers expect this to encourage similar AI integrations across Asia and beyond in coming years.

Overall the move highlights growing convergence of computing and biology for efficient production.